作者
Kevin Tyan, Shilpa Grover, Michael Dougan, Ryan J Sullivan, Anita Giobbie-Hurder, Steven Blum, Jeffrey Joseph Ishizuka, Taha Qazi, Rawad Elias, Kruti Vora, Alex Ruan, William Martin-Doyle, Lauren Eastman, Meredith Davis, Maria Gargano, Rizwan Haq, Elizabeth Iannotti Buchbinder, Patrick Alexander Ott, F Stephen Hodi, Osama E Rahma
发表日期
2020/2/10
来源
Journal of Clinical Oncology
卷号
38
期号
5_suppl
页码范围
89-89
出版商
American Society of Clinical Oncology
简介
89
Background: There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis. Methods: We performed a retrospective analysis of melanoma patients at Dana-Farber Cancer Institute who received PD-1, CTLA-4, or combination blockade between May 2011 to October 2017. Clinical and laboratory characteristics associated with pathologically confirmed ICI colitis were evaluated using multivariate logistic regression analyses. External validation was performed on an independent cohort from Massachusetts General Hospital. Results: The discovery cohort included 213 patients of whom 37 developed ICI colitis (17%). The odds of colitis were higher in patients treated with ipilimumab either as monotherapy or in combination with nivolumab compared to those …
学术搜索中的文章
K Tyan, S Grover, M Dougan, RJ Sullivan… - 2020